Loading…
Novartis AG is projected to rise to $178.29 by 2027, a +15% move from its current price of $154.62. NVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $152.57 | $154.67 | $156.81 | +0.04% |
| Jul 14 | $151.76 | $154.73 | $157.76 | +0.07% |
| Jul 15 | $151.15 | $154.78 | $158.50 | +0.11% |
| Jul 16 | $150.65 | $154.84 | $159.14 | +0.14% |
| Jul 17 | $150.22 | $154.89 | $159.71 | +0.18% |
| Jul 18 | $149.83 | $154.95 | $160.24 | +0.21% |
| Jul 19 | $149.48 | $155.00 | $160.72 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $149.48 | $155.00 | $160.72 | +0.25% |
| Week 2 | $147.62 | $155.39 | $163.56 | +0.50% |
| Week 3 | $146.29 | $155.77 | $165.86 | +0.74% |
| Week 4 | $145.23 | $156.16 | $167.90 | +0.99% |
| Week 5 | $144.35 | $156.54 | $169.76 | +1.24% |
| Week 6 | $143.59 | $156.93 | $171.50 | +1.49% |
| Week 7 | $142.93 | $157.32 | $173.15 | +1.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Novartis AG is a pharmaceutical company incorporated in 1996 and headquartered in Basel, Switzerland. It researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Its portfolio includes Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graft-versus-host disease (GvHD). It also provides Tasigna to treat Philadelphia chromosome-positive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosinusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly, carcinoid tumors and other types of functional gastrointestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of the genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis (NVS) is a pharmaceutical company with a current price of $159.90 and a market capitalization of $294.11B. Its market rank is 5470. The forecasted price path shows a bullish long-term trajectory, with average prices rising from $159.90 in 2026 to $308.38 by 2030, $665.26 by 2040, and $1,387.14 by 2050.
Projected ROIs reinforce the upside: 92.9% in 2030, 316.1% in 2040, and 767.5% in 2050.
A major floor 12.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 9.2% above — clearing it would confirm fresh momentum.
Key NVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $155.27 | Sell | $155.08 | Sell |
| MA 10 | $156.01 | Sell | $155.04 | Sell |
| MA 20 | $153.91 | Buy | $153.88 | Buy |
| MA 50 | $150.35 | Buy | $151.97 | Buy |
| MA 100 | $152.83 | Buy | $150.02 | Buy |
| MA 200 | $144.30 | Buy | $143.96 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.70 | Neutral |
| Stoch RSI (14) | 17.10 | Buy |
| CCI (20) | 4.32 | Neutral |
| Williams %R (14) | -53.33 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | 0.44 | Buy |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 46.67 | Neutral |
| TRIX (15) | 0.17 | Buy |
| Awesome (5,34) | 3.52 | Buy |
| Ultimate (7,14,28) | 49.45 | Neutral |
| Momentum (10) | -1.07 | Sell |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 154.52 | Buy |
| ADX (14) | 12.46 | Neutral |
| ATR (14) | 1.95 | Info |
The 30-day technical picture is bullish. RSI(14) is 60, with SMA50 at $149.43 and SMA200 at $143.49. Support sits at $143.48 and resistance at $159.90. The 30-day price range runs from $145.50 to $175.73.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $137.91 | $154.62 | $206.81 | 0% | Neutral | |
| $146.01 | $178.29 | $227.61 | +15% | Neutral | |
| $173.04 | $215.26 | $282.23 | +39% | Bullish | |
| $197.89 | $249.97 | $334.72 | +62% | Bullish | |
| $223.01 | $285.51 | $389.19 | +85% | Bullish | |
| $242.27 | $313.94 | $434.72 | +103% | Bullish | |
| $243.42 | $319.00 | $448.00 | +106% | Bullish | |
| $264.43 | $350.19 | $498.17 | +126% | Bullish | |
| $281.41 | $376.38 | $541.82 | +143% | Bullish | |
| $294.88 | $398.13 | $579.52 | +157% | Bullish | |
| $420.63 | $592.32 | $903.52 | +283% | Bullish | |
| $806.08 | $1,217.39 | $1,990.55 | +687% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $137.91 | $154.62 | $186.75 | +0.00% |
| August 2026 | $136.72 | $160.06 | $191.45 | +3.52% |
| September 2026 | $135.74 | $159.68 | $192.48 | -0.24% |
| October 2026 | $138.72 | $163.85 | $198.81 | +2.61% |
| November 2026 | $142.67 | $169.10 | $206.30 | +3.20% |
| December 2026 | $141.84 | $168.65 | $206.81 | -0.26% |
Click any year to see its month-by-month NVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NVS to range from $137.91 to $206.81 through 2026. The $154.62 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The NVS price prediction for 2027 points to an average of $178.29 (low $146.01, high $227.61) — a potential gain of +15% on today's $154.62. A consolidation phase looks the most probable path here.
In 2028, NVS is projected to trade between $173.04 and $282.23, averaging $215.26 — a potential gain of +39% from today's $154.62. That is up +21% on the projected 2027 average. Momentum favours further upside here.
Novartis AG's 2029 outlook centres on $249.97, within a $197.89 to $334.72 range. That is up +16% on the projected 2028 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, NVS could reach as high as $389.19, with a base case around $285.51 and support toward $223.01 — roughly +85% from $154.62. Momentum favours further upside here.
Expect NVS to range from $242.27 to $434.72 through 2031. The $313.94 average target implies a +103% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The NVS price prediction for 2032 points to an average of $319.00 (low $243.42, high $448.00) — a potential gain of +106% on today's $154.62. Momentum favours further upside here.
In 2033, NVS is projected to trade between $264.43 and $498.17, averaging $350.19 — a potential gain of +126% from today's $154.62. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Novartis AG's 2034 outlook centres on $376.38, within a $281.41 to $541.82 range. That is up +7% on the projected 2033 average. That marks a +143% change versus current levels. Momentum favours further upside here.
By 2035, NVS could reach as high as $579.52, with a base case around $398.13 and support toward $294.88 — roughly +157% from $154.62. Buyers look set to stay in control over this stretch.
Expect NVS to range from $420.63 to $903.52 through 2040. The $592.32 average target implies a +283% move from current prices. That is up +49% on the projected 2035 average. Momentum favours further upside here.
The NVS price prediction for 2050 points to an average of $1,217.39 (low $806.08, high $1,990.55) — a potential gain of +687% on today's $154.62. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVS today (≈ 6.467469 NVS) could be worth
$7,873.41
+$6,873.41 (+687%) by 2050 · US Dollar
Based on the average projected NVS price of $1,217.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVSwould be worth at today's price.
$1,000 invested in NVS on Jul 10, 2025 (≈ 8.082114 NVS) would be worth
$1,249.66
+$249.66 (+25.0%) today · 1.25× · US Dollar
Based on a NVS entry price of $123.73 vs. today's $154.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $159.9 | $966.98 | -3.3% |
| 1 month ago | $148.12 | $1,043.88 | +4.4% |
| 3 months ago | $154.05 | $1,003.7 | +0.4% |
| 6 months ago | $141.82 | $1,090.26 | +9.0% |
| 1 year ago | $123.73 | $1,249.66 | +25.0% |
| All time (5.0y) ago | $92.67 | $1,668.5 | +66.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVS forecast.
Our base-case forecast reaches $310.00 around 2031.
Implied market cap at $310.00: $591.51B
The multi-year outlook shows a bullish trajectory across 2028 through 2050. The sentiment turns bullish from 2028 onward, with the 2030 average price at $308.38 and a 92.9% return on investment. By 2040, the average is $665.26 with a 316.1% ROI, highlighting substantial upside potential alongside continued bullish momentum.
By 2050, the average is $1,387.14 and the ROI is 767.5%, sustaining a bullish stance. These are estimates and not guarantees; actual results may vary.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $308.38, a range from $240.82 to $420.53, with an ROI of 92.9% and a bullish sentiment.
The long-term forecast shows a bullish sentiment through 2050, with average price reaching $1,387.14 and an ROI of 767.5% by 2050; 2030 averages and ROIs also indicate upside (e.g., $308.38 avg and 92.9% ROI).
Yes. The 2040 forecast max is $1,014.97, which exceeds $1,000, while the 2040 average is $665.26 and ROI is 316.1%.
The near-term path shows 2026 with an average price of $159.90 and 2027 with an average of $188.19.
Current price is $159.90 and market cap is $294.11B.
Novartis AG Community Discussion
0Share your Novartis AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.